BackInnate Pharma S.A. Overview
Innate Pharma S.A.

Innate Pharma S.A. Return on Equity

Innate Pharma S.A. (IPHYF) has a ROE of 231.07%, above the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

231.07%

Return on Equity

231.07%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Innate Pharma S.A. (IPHYF) FAQ

The latest ROE for IPHYF is 231.07%. That is above the Healthcare sector average of 13.1%. Investors often review this figure alongside Innate Pharma S.A.'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, IPHYF currently prints 231.07% for ROE, while the sector average sits near 13.1%. That is roughly 1663.4% above the sector mean. Large gaps often invite a closer look at Innate Pharma S.A.'s growth, margins, and balance sheet.

Return on Equity shows how effectively Innate Pharma S.A. converts resources into returns. At 231.07%, IPHYF may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IPHYF's ROE (231.07%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Innate Pharma S.A.'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.

Questions & Answers